Jounce Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Jounce Therapeutics's estimated annual revenue is currently $89.3M per year.
- Jounce Therapeutics's estimated revenue per employee is $464,844
- Jounce Therapeutics's current valuation is $321.8M. (January 2022}
Employee Data
- Jounce Therapeutics has 192 Employees.
- Jounce Therapeutics grew their employee count by -2% last year.
Jounce Therapeutics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -94% | N/A | N/A |
#2 | $2.6M | 17 | N/A | N/A | N/A |
#3 | $6M | 39 | -20% | $176.5M | N/A |
#4 | $4.5M | 29 | N/A | N/A | N/A |
#5 | $2.6M | 17 | N/A | N/A | N/A |
#6 | N/A | 145 | -21% | $39.5M | N/A |
#7 | N/A | 0 | N/A | $9.5M | N/A |
#8 | $15.9M | 159 | -39% | $135M | N/A |
#9 | $1.7M | 11 | 57% | $20.9M | N/A |
#10 | $2.8M | 18 | 50% | $28.9M | N/A |
What Is Jounce Therapeutics?
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide longlasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS. For more information, please visit http://jouncetx.com/ We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients lives.
keywords:Biotechnology,Enterprise Software,Healthcare,Human Resources Hr,Pharmaceuticals
N/A
Total Funding
192
Number of Employees
$89.3M
Revenue (est)
-2%
Employee Growth %
$321.8M
Valuation
N/A
Accelerator
Jounce Therapeutics News
The early stage biotech company, with a focus on cancer immunotherapy and targeted therapeutics, has raised $102 million in private funding to date, from investors such as Third Rock. Jounce is listed on the NASDAQ Capital Market under the ticker symbol “JNCE”. Jounce’s lead compound, JTX-2011 ...
Shares of Jounce rose 65.5% on the Nasdaq when markets opened Tuesday and were still up more than 47% in late-morning trading. Gilead’s shares fell by 2.5%. JTX-1811 is a monoclonal antibody that targets the chemokine receptor CCR8, thereby depleting immunosuppressive tumor-infiltrating T-regul ...
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000, ...
A look at the shareholders of Jounce Therapeutics, Inc. (NASDAQ:JNCE) can tell us which group is most powerful. Insiders often own a large ...
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the ...
Jounce Therapeutics, Inc. (NASDAQ:JNCE) is one of the worst performers on the stock market today. At current price of $3.57, the shares have ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29.9M | 192 | -13% | $19.5M |
#2 | $53M | 192 | 10% | N/A |
#3 | $30.6M | 192 | -5% | N/A |
#4 | $44.4M | 192 | 15% | N/A |
#5 | $53M | 192 | 20% | N/A |
